Lebanon, 2004 Medicine price survey in Lebanon, 2004 undertaken by Dr Rita Karam, Ministry of Health Marg Ewen (on behalf of Dr Karam) WHO/HAI post-medicine.

Slides:



Advertisements
Similar presentations
Multiplication X 1 1 x 1 = 1 2 x 1 = 2 3 x 1 = 3 4 x 1 = 4 5 x 1 = 5 6 x 1 = 6 7 x 1 = 7 8 x 1 = 8 9 x 1 = 9 10 x 1 = x 1 = x 1 = 12 X 2 1.
Advertisements

Division ÷ 1 1 ÷ 1 = 1 2 ÷ 1 = 2 3 ÷ 1 = 3 4 ÷ 1 = 4 5 ÷ 1 = 5 6 ÷ 1 = 6 7 ÷ 1 = 7 8 ÷ 1 = 8 9 ÷ 1 = 9 10 ÷ 1 = ÷ 1 = ÷ 1 = 12 ÷ 2 2 ÷ 2 =
National experiences of regular price monitoring Klara Tisocki, WHO/HAI medicine price project Towards equitable and affordable medicine prices policy.
Results of the Jordan medicine price and availability survey conducted in 2004.
Introduction of the Annual Report 1. Workshop towards equitable and affordable medicine prices policy in Jordan Dead Sea, Jordan Dead Sea, Jordan 4–5.
Medicine Prices Matter to People and Insurance Companies Margaret Ewen Health Action International.
Strategies to improve the acceptance and use of generics. Jordan Pharmaceutical Association Dr.Taher Shakhashir.
Direct costs and availability of diabetes medicines in low-income and middle-income countries Birgit Volman 27/08/2008 Meeting on Access to Medicines for.
1 Paying the Price Margaret Ewen Health Action International Europe.
1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
August 27th Availability, Pricing and Affordability of Asthma Medicines Presentation for Meeting on Availability, Pricing and Affordability.
1 Medicines for Chronic Diseases: too costly, too scarce, too important to ignore Margaret Ewen Health Action International.
Completing the Medicine Price Data Collection form Presentation template for adaptation and use in medicine prices and availability survey training workshop.
Strategies to Improve Efficiency in Medicine Procurement Towards equitable and affordable medicine prices policies in Jordan Workshop 4-5 Dec, 2007 Dr.
MEDICINES PRICES IN INDONESIA Ms. Selma Siahaan Center for Health Services and Technology R&D National Institute of Health R&D Indonesia 14 June 2006.
1 Medicine Availability, Prices and Affordability in West Bengal, India (2004) DALIA DEY CUTS & CDMU.
1 Medicine Prices, Availability and Affordability Margaret Ewen Health Action International.
Overview of the medicine prices and availability survey methodology Presentation template for adaptation and use in medicine prices and availability survey.
Syria,2004 Medicine price survey in Syria, 2004 undertaken by Pharmaceutical Studies Directorate, Ministry of Health Presentation by Razan Sallouta WHO/HAI.
A MEDICINE PRICES SURVEY IN CHINA Presentation by Dr Xiaoxia Hu Research by Dr Sun Qiang and Dr Xiaoxia Hu June, 2006.
1 Introduction to the medicine prices and availability survey and training workshop Presentation template for adaptation and use in medicine prices and.
Mohamed Izham Mohamed Ibrahim
August 27th Availability, Pricing and Affordability of Cardiovascular Medicines Draft report for comments Maaike S.M. van Mourik University.
The prices of medicines worldwide & how they are determined Margaret Ewen Health Action International Europe Co-ordinator WHO/HAI Project on Medicine Prices.
Measuring Medicine Prices and Availability – a new Methodology and few Indian Survey Results Dr. Anita Kotwani Department of Pharmacology Vallabhbhai Patel.
MDG Target 8.E gap analysis Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical Policies, World Health Organization 27 August 2008.
Price, availability and affordability of medicines international comparison of 29 surveys Presented by: Richard Laing World Health Organization, Geneva.
Essential Medicines & Pharmaceutical Policies DHS/EMRO WHO Perspective on Medicine Prices & Policies Meeting of Drug Board on Medicine Pricing Federal.
Medicine Prices and Affordability Survey in West Bengal, India ( )
Understanding the Antimalarials Market in Uganda Rosette Mutambi, HEPS Uganda Martin Auton, Health Action International, The Netherlands ASTMH, December.
OPTN Modifications to Heart Allocation Policy Implemented July 12, 2006 Changed the allocation order for medically urgent (Status 1A and 1B) patients Policy.
THE COMMONWEALTH FUND Figure 1. Health Insurance Coverage and Uninsured Trends Data: Analysis of the U.S. Census Bureau, Current Population Survey Annual.
Ministry of Health National STD/AIDS Programme Universal Access to Antiretroviral Therapy: The Brazilian Experience.
1 MDG Target 8.E gap analysis Dr Hans Hogerzeil Director, Department of Essential Medicines and Pharmaceutical Policies, World Health Organization October.
Add Governors Discretionary (1G) Grants Chapter 6.
Tennessee Higher Education Commission Higher Education Recommendations & Finance Overview November 15, 2012.
1 1  1 =.
1  1 =.
The 5S numbers game..
Overview of Rural Health Care Ethics Training materials from Rural Health Care Ethics: A Manual for Trainers. WA Nelson and KE Schifferdecker, Dartmouth.
THE COMMONWEALTH FUND Multinational Comparisons of Health Systems Data, 2013 David Squires The Commonwealth Fund November 2013.
The basics for simulations
Look at This PowerPoint for help on you times tables
TCCI Barometer March “Establishing a reliable tool for monitoring the financial, business and social activity in the Prefecture of Thessaloniki”
TCCI Barometer March “Establishing a reliable tool for monitoring the financial, business and social activity in the Prefecture of Thessaloniki”
Medicine prices: a WHO/Health Action International collaboration The approach, some results, and implications for policy to improve the affordability of.
Progressive Aerobic Cardiovascular Endurance Run
TCCI Barometer September “Establishing a reliable tool for monitoring the financial, business and social activity in the Prefecture of Thessaloniki”
Example of a Decision Tree Problem: The Payoff Table
2011 WINNISQUAM COMMUNITY SURVEY YOUTH RISK BEHAVIOR GRADES 9-12 STUDENTS=1021.
Before Between After.
Benjamin Banneker Charter Academy of Technology Making AYP Benjamin Banneker Charter Academy of Technology Making AYP.
2011 FRANKLIN COMMUNITY SURVEY YOUTH RISK BEHAVIOR GRADES 9-12 STUDENTS=332.
Commonwealth Connector Minimum Pharmacy Standards October 11, 2007.
Static Equilibrium; Elasticity and Fracture
Resistência dos Materiais, 5ª ed.
Schutzvermerk nach DIN 34 beachten 05/04/15 Seite 1 Training EPAM and CANopen Basic Solution: Password * * Level 1 Level 2 * Level 3 Password2 IP-Adr.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, November 3 rd 2010 Alexandra Cameron, Department of Essential Medicines.
1 Generating reliable evidence: measuring medicine prices and availability Dr Richard Laing Department of Essential Medicines and Pharmaceutical Policy.
EDM STRATEGY FOR WORKING WITH COUNTRIES-TANZANIA Rose Shija EDM NPO TANZANIA.
Paying the Price: The Affordability of Medicines Across the Commonwealth (and elsewhere) Margaret Ewen Health Action International.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, November 18 th 2009 Alexandra Cameron, Department of Essential Medicines.
ASSESSMENT OF AVAILABILITY, PRICE AND AFFORDABILITY OF MEDICINES FOR CHILDREN IN GHANA Authors: Gyansa-Lutterodt M. 1,Andrews Annan E. 2, Koduah A. 1,
Tanzania1. 2 Tanzania Assessment Gabriel Upunda Tanzania3 DemographicsTanzania Area (sq km)945,100 Population 32,900,000 25% urban GNP per capitaUS $240.
Medicine Prices, Availability, Affordability and Price Components in Kazakhstan, Kyrgystan, Tajikistan & Uzbekistan Margaret Ewen Health Action International.
Efficiency of Public Procurement of Medicines in the Philippines Klara Tisocki, Douglas Ball Health Action International.
1 Medicine price and availability surveys – methodology essentials – policy options Richard Laing Department of Essential Medicines and Pharmaceutical.
Zokufa HZ, Pillay T Pharmaceutical Policy and Planning National Department of Health- South Africa.
Out-of-pocket and Out-of-reach Margaret Ewen, Coordinator, Global Projects (Pricing) Health Action International Amsterdam.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, 2012 Richard Laing with materials provided by Alexandra Cameron, Department.
Presentation transcript:

Lebanon, 2004 Medicine price survey in Lebanon, 2004 undertaken by Dr Rita Karam, Ministry of Health Marg Ewen (on behalf of Dr Karam) WHO/HAI post-medicine price survey regional workshop, Cairo 7-9 January 2007

Lebanon, 2004 Country background Population in millions: 4 (excluding foreign residents & refugees) Population in millions: 4 (excluding foreign residents & refugees) % of rural population: 85 % % of rural population: 85 % Total adult literacy rate: 88 % Total adult literacy rate: 88 % GDP per capita: 5611 US $ GDP per capita: 5611 US $ Total health expenditure: 10.4 % of GDP Total health expenditure: 10.4 % of GDP Government health expenditure 29.3% of total health expenditure Government health expenditure 29.3% of total health expenditure Public sector – medicines supplied by MoH (free) and NSSF (75-80% of patient price reimbursed) Public sector – medicines supplied by MoH (free) and NSSF (75-80% of patient price reimbursed)

Lebanon, 2004 Methodology Number of medicines surveyed: 32 Core 26 Supplementary 6 Year of MSH reference price used: 2002 Number of regions surveyed: 4 Total number of facilities sampled: Sector (patient prices) Number Public20 Private retail pharmacies 40 OtherNS

Lebanon, 2004 Availability PublicPrivate IBLPGIBLPG Median availability 0%0%95%84%

Lebanon, 2004 Prices: summary MPRs and examples ProcurementPublicPrivate IBLPGIBLPGIBLPG Median MPR free ciprofloxacin metronidazole beclometasone IB = innovator brand LPG = lowest priced generic

Lebanon, 2004 Affordability (No. of days wages) Daily wage (US$) PublicPrivate = $6.60 IB LPG LPG IBIBIBIB IB LPG Amoxicillin 500mg tabs, 21 free free Captopril 25mg tab, Ranitidine 150mg tabs,

Lebanon, 2004 Price components Official figures: imported medicine Type of charge Charge basis Amount of charge Price of dispensed quantity Cumulative % mark-up FOB20000% Shipping/insurancepercent7.5% % Customs/clearancepercent11.5% % Importers mark-up percent10% % Pharmacy mark-up percent30% % Official figures: locally manufactured medicine Manufacturers selling price 10000% Distributors mark-up percent10%110010% Pharmacy mark-up percent30%143043%

Lebanon, 2004 Main Findings Public sector procurement prices vary from acceptable to high Public sector procurement prices vary from acceptable to high Availability of medicines in the public sector is extremely poor Availability of medicines in the public sector is extremely poor Availability of medicines in private retail pharmacies is good Availability of medicines in private retail pharmacies is good Prices are very high for both generics and innovator brands in the private sector Prices are very high for both generics and innovator brands in the private sector

Lebanon, 2004 Recommendations Develop a National Drug Policy Develop a National Drug Policy Annual budget allocation for essential medicines in the public sector Annual budget allocation for essential medicines in the public sector Unify public sector procurement, use tenders Unify public sector procurement, use tenders Streamline the public sector supply system Streamline the public sector supply system Review the pricing scheme in order to lower prices Review the pricing scheme in order to lower prices Permit and encourage generic substitution Permit and encourage generic substitution

Lebanon, 2004 Follow-up activities 2004: Committee of 4 pharmacists compared FOB prices of about 2200 imported medicines with prices paid by Saudi Arabia & Jordan. Outcome: 1100 meds (25% of all registered medicines) had FOB price reduced by 20-30% Committee of 4 pharmacists compared FOB prices of about 2200 imported medicines with prices paid by Saudi Arabia & Jordan. Outcome: 1100 meds (25% of all registered medicines) had FOB price reduced by 20-30% Budget increased for cancer, HIV & other specialised medicines from $14M per annum to $40M Budget increased for cancer, HIV & other specialised medicines from $14M per annum to $40M

Lebanon, : Implemented a new pricing structure for all imported medicines, estimated to reduce patient prices by 3-15% FOB $ ShippingInsuranceCustomsClearanceImporterMarkupPharmacyMarkupCumulat.Markup 0- $10 0- $106%10%10%30%66% $10 - $50 4.5%8.5%10%30%62% $50 - $ %7.5%9%27%54% > $ %6.5%8%24%46%

Lebanon, : Information on patient prices & pharmacy margin included on MoH website. Updated every 2 weeks. 2007: First Lebanese National Formulary to be distributed in April to all doctors & pharmacists. Comparative information on brand/generic products registered in Lebanon, strength/dosage form, country of origin, price and coverage by NSSF. To be updated annually. First Lebanese National Formulary to be distributed in April to all doctors & pharmacists. Comparative information on brand/generic products registered in Lebanon, strength/dosage form, country of origin, price and coverage by NSSF. To be updated annually. Project to review price structure of locally manufactured medicines (700, generics, prices quite low) Project to review price structure of locally manufactured medicines (700, generics, prices quite low)2008/2009: Implementing a re-pricing scheme for all medicines – reducing the FOB price